New insights into the management of secondary hyperparathyroidism in non-dialysis dependent chronic kidney disease: extended release calcifediol.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert practice algorithm without systematic review methodology or new human data
PubMed 42227696 · doi:10.1093/joneph/aajaf008
What was done
This narrative review analyzed secondary hyperparathyroidism management in non-dialysis dependent chronic kidney disease (NDD-CKD stages 3-4) in Switzerland. The authors examined vitamin D insufficiency, monitoring practices for bone and mineral parameters, KDIGO guidelines, and the role of extended-release calcifediol to construct a clinical treatment algorithm.
What was found
The abstract reports no numerical trial results or effect sizes. It highlights a lack of definitive clinical endpoints and proposes initiating therapy at a 25(OH)D threshold under 30 ng/mL (<75 nmol/L) to achieve target concentrations of 30-100 ng/mL (75-250 nmol/L). It reports that extended-release calcifediol shows biochemical efficacy in raising 25(OH)D and lowering parathyroid hormone, while evidence for high-dose cholecalciferol remains heterogeneous.
Why it matters
It provides clinicians with a structured treatment algorithm and pragmatic target ranges for using extended-release calcifediol to address secondary hyperparathyroidism in pre-dialysis CKD.
Limits
As a narrative review, it presents expert guidance without systematic search methodology or new primary data. The abstract provides no quantitative data, focuses on biochemical surrogate endpoints rather than clinical outcomes, and reflects a regionally tailored perspective (Switzerland).
Cited by
- contradicts Rayaldee is a pre-activated vitamin D prescribed for multiple sclerosis.